1. DuBuske L. Efficacy and safety of sublingual allergen immunotherapy. Allergy Asthma Proc 2022; 43: 272-80.
2.
Creticos PS, Gunaydin FE, Nolte H, et al. Allergen Immunotherapy: the evidence supporting the efficacy and safety of subcutaneous immunotherapy and sublingual forms of immunotherapy for allergic rhinitis/conjunctivitis and asthma. J Allergy Clin Immunol Pract 2024; 12: 1415-27.
3.
Farraia M, Paciência I, Castro Mendes F, et al. Allergen immunotherapy for asthma prevention: a systematic review and meta-analysis of randomized and non-randomized controlled studies. Allergy 2022; 77: 1719-35.
4.
Platts-Mills TA. The allergy epidemics: 1870-2010. J Allergy Clin Immunol 2015; 136: 3-13.
5.
Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347: 911-20.
6.
Krishna MT, Subramanian A, Adderley NJ, et al. Allergic diseases and long-term risk of autoimmune disorders: longitudinal cohort study and cluster analysis. Eur Respir J 2019; 54: 1900476.
7.
Phanuphak P, Kohler PF. Onset of polyarteritis nodosa during allergic hyposensitization treatment. Am J Med 1980; 68: 479-85.
8.
Turkcapar N, Kinikli G, Sak SD, Duman M. Specific immunotherapy-induced Sjögren’s syndrome. Rheumatol Int 2005; 26: 182-4.
9.
Nakajima H, Ohtsuka S, Nishina T, et al. Multiple sclerosis after allergen-specific immunotherapy and influenza vaccination. Eur Neurol 2003; 50: 248-9.
10.
Morfín Maciel BM, Castillo Morfín BM. Esclerodermia relacionada con inmunoterapia específica. Comunicación de un caso [Scleroderma related to specific immunotherapy. A report of a case]. Rev Alerg Mex 2009; 56: 136-45.
11.
Ghoreschi K, Fischer J, Biedermann T. Manifestation of rheumatoid arthritis during subcutaneous allergen-specific immunotherapy with bee venom. J Allergy Clin Immunol 2012; 130: 1438-9.
12.
Quirce S, Fernandez Rivas M, Losada E, et al. Recurrent pericarditis: a rare complication of allergen immunotherapy. Allergy 1992; 47: 343-5.
13.
Berbis P, Carena MC, Auffranc JC, Privat Y. Vascularite nécrosante cutanéo-systémique survenue en cours de désensibilisation [Cutaneo-systemic necrotizing vasculitis occurring during desensitization]. Ann Dermatol Venereol 1986; 113: 805-10.
14.
Taylor RJ. Hypersensitivity vasculitis occurring in a patient receiving immunotherapy. J Allergy Clin Immunol 1991; 87: 889-90.
15.
Cabrera GE, Citera G, Gutiérrez M, et al. Digital vasculitis following allergic desensitization treatment. J Rheumatol 1993; 20: 1970-2.
16.
Branco-Ferreira M, Clode MH, Palma-Carlos AG. Distal digital vasculitis induced by specific immunotherapy. Allergy 1998; 53; 102-3.
17.
Sánchez-Morillas L, Reaño Martos M, Iglesias Cadarso A, et al. Vasculitis during immunotherapy treatment in a patient with allergy to Cupressus arizonica. Allergol Immunopathol (Madr) 2005; 33: 333-4.
18.
Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26: 6630-8.
19.
Linneberg A, Madsen F, Skaaby T. Allergen-specific immunotherapy and risk of autoimmune disease. Curr Opin Allergy Clin Immunol 2012; 12: 635-9.
20.
Salvetti M, Pisani A, Bastianello S, et al. Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol 1995; 242: 143-6.
21.
Fiorillo A, Fonacier L, Diola C. Safety of allergenic immunotherapy in systemic lupus erythematosus. J Allergy Clin Immunol 2006; 117 2 Suppl: S264.
22.
Fujioka K, Kasahara A, Kida T, et al. Effectiveness and safety of allergen immunotherapy in patients with allergic rhinitis complicated by rheumatic autoimmune diseases: a case series study. Allergy Asthma Clin Immunol 2022; 18: 63.
23.
Linneberg A, Jacobsen RK, Jespersen L, Abildstrøm SZ. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 2012; 129: 413-9.
24.
Bozek A, Kozłowska R, Jarzab J. The safety of specific immunotherapy for patients allergic to house-dust mites and pollen in relation to the development of neoplasia and autoimmune disease: a long-term, observational case-control study. Int Arch Allergy Immunol 2014; 163: 307-12.
25.
Specific allergen immunotherapy for asthma. A position paper of the Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. Med J Aust 1997; 167: 540-4.
26.
Walker SM, Durham SR, Till SJ, et al.; British Society for Allergy and Clinical Immunology. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011; 41: 1177-200.
27.
Bolle R, Berstad A, Florvaag E, Steinsvåg S. Praktisk veileder I allergivaksinasjon 2. Norsk kvalitetssikringsdokument for Hyposensibilisering –Allergenspesifikk immunterapi – Allergivaksinasjon. Norwegian Society of Allergology and Immunopathology (Norsk Forening for Allergologi og Immunpatologi, NSAI), 2011.
28.
Jutel M, Gonerko P, Cichocka-Jarosz E, Samoliński B. Grupa Robocza Sekcji Immunoterapii PTA. Stanowisko Sekcji Immunoterapii Polskiego Towarzystwa Alergologicznego w sprawie prowadzenia alergenowo swoistej immunoterapii (AIT) u pacjentów zagrożonych wystąpieniem lub z rozpoznanymi chorobami na tle autoimmunizacji. Alergol Pol 2015; 2: 28-36.
29.
Pitsios C, Demoly P, Bilò MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy 2015; 70: 897-909.
30.
Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014; 23: 282-319.
31.
Lee HY, Lee SM, Kang SY, et al.; Korean Academy of Asthma Allergy and Clinical Immunology (KAAACI) Allergen Immunotherapy and Allergen Working Group. KAAACI Guidelines for Allergen Immunotherapy. Allergy Asthma Immunol Res 2023; 15: 725-56.
32.
Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127 (1 Suppl): S1-55.
33.
Larenas-Linnemann D, Ortega-Martell J, del Río-Navarro B, et al. Guía Mexicana de Práctica Clínica de Inmunoterapia. Rev Alerg Mex 2011; 58: 3-51.
34.
De Luque-Piñana V, Guardia Martínez P, Moreno Aguilar C. Manejo práctico de inmunoterapia. In: Guardia Martínez P, Moreno Aguilar C, Tabar Purroy AI, editors. Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas, Comité de Inmunoterapia SEAIC-2010. Barcelona: ESMONpharma 2011; 23-30.
35.
Del Rio PR, Pitsios C, Tsoumani M, et al. Physicians’ experience and opinion on contraindications to allergen immunotherapy: the CONSIT survey. Ann Allergy Asthma Immunol 2017; 118: 621-8.e1.
36.
Lommeguide i praktisk allergen-specifik immunterapi. Baseret på EAACI Immunotherapy Interest Group Standards for Practical Allergen-Specific Immunotherapy. Danish Society for Allergology (Dansk Selskab for Allergologi, DSA), 2005.
37.
Arvidsson M, Odebäck P, Eriksson M, et al. Allergenspecifik immunterapi Rekommendationer för läkare och sjuksköterskor Revidering av tidigare rekommendationer från år 2000 Sammanställda på uppdrag av Svenska Föreningen för Allergologi 2009 Arbetet har finansierats av Svenska Föreningen För Allergologi. Arbetsgrupp Swedish Association For Allergology.
38.
Pajno GB, Bernardini R, Peroni D, et al.; Allergen-specific Immunotherapy panel of the Italian Society of Pediatric Allergy and Immunology (SIAIP). Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatr 2017; 43: 13.
39.
Okubo K, Kurono Y, Ichimura K, et al.; Japanese Society of Allergology. Japanese guidelines for allergic rhinitis 2020. Allergol Int 2020; 69: 331-45.
40.
Wang C, Bao Y, Chen J, et al.; Chinese Society of Allergy (CSA) and Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G). Chinese guideline on allergen immunotherapy for allergic rhinitis: the 2022 update. Allergy Asthma Immunol Res 2022; 14: 604-52.
41.
Aarestrup FM, Lira GVAG, Taketomi EA, et al. Brazilian guidelines for allergen immunotherapy in the treatment of allergic rhinitis. Rev Assoc Med Bras 2023; 69: e2023D695.
42.
Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2018; 73: 744-64.
43.
Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol 2023; 23: 317-28.
44.
Jutel M, Gonerko P, Cichocka-Jarosz E, Samoliński B. Stanowisko Sekcji Immunoterapii Polskiego Towarzystwa Alergologicznego w sprawie prowadzenia alergenowo swoistej immunoterapii (AIT) u pacjentów zagrożonych wystąpieniem lub z rozpoznanymi chorobami na tle autoimmunizacji. Alergol Pol 2015; 2: 28-36.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
